BCAAs
Leucine, isoleucine & valine — popular for recovery, but not muscle-building on their own.
What is BCAAs?
BCAAs (Branched-Chain Amino Acids) is a performance supplement used for reduce muscle soreness (doms). NutriDex grades the human evidence as Mixed. BCAAs are three essential amino acids — leucine, isoleucine and valine — sold for muscle growth, recovery and reduced fatigue. The evidence is genuinely split. Meta-analyses show BCAA supplementation meaningfully lowers delayed-onset muscle soreness (effect size ~0.7) and the muscle-damage marker creatine kinase, but has no effect on lactate dehydrogenase or actual exercise performance. Crucially, controlled tracer studies show that taking BCAAs alone raises muscle protein synthesis only ~22% — roughly half the response to an equivalent dose of whey — because building muscle requires all nine essential amino acids, not just three. A leading review concluded the claim that dietary BCAAs alone are anabolic is 'unwarranted.' In cirrhosis, BCAAs do improve hepatic encephalopathy symptoms (Cochrane), though without lowering mortality. For most well-fed people eating enough protein, BCAAs add little over food or whey.
Purported Benefits
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Reduces delayed-onset muscle soreness (DOMS)Meta-analyses show a real reduction in soreness (ES ~0.73); higher dose/longer use works best. | Moderate | ↑ benefit · moderate | 2 |
| Lowers creatine kinase (muscle damage)Multiple meta-analyses show lower CK after exercise but no effect on LDH; marker-level, not performance. | Moderate | ↑ benefit · small | 2 |
| Improves muscle performance / anabolic responseBCAAs alone raise MPS only ~22% (half of whey); umbrella review finds no performance-recovery benefit, claim 'unwarranted'. | Mixed | — no effect · negligible | 3 |
| Improves hepatic encephalopathy in cirrhosisCochrane (18 RCTs) shows improved HE symptoms (RR 0.73) but no mortality benefit. | Moderate | ↑ benefit · moderate | 1 |